1
2011 Progress Report • Pr e-clinical studies continuing as planned – Toxicology – Biodistribution – Assay Development
www.immunomix.com
2
2011 Progress Report • F unding Activities Continue – Cash position is very good – Seeking additional funding to cover Phase II / 2012
www.immunomix.com
3
2011 Progress Report • Chimer ic Vaccine Patent I ssued in Japan – New Patent in preparation – Excellent patent position for ITI
www.immunomix.com
4
2011 Progress Report • N ew Oppor tunities D eveloping – Become Basic in Operations – Animal Health market
www.immunomix.com
5
2011 Funding Strategy • F unding Plan – N ew PPM - Launching new initiative for $2 million raise
at $1.66 per share (common stock)
www.immunomix.com
6
Questions?
www.immunomix.com
7
8